株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

放射性医薬品:各種技術と世界の市場

Radiopharmaceuticals: Technologies and Global Markets

発行 BCC Research 商品コード 311757
出版日 ページ情報 英文 189 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
放射性医薬品:各種技術と世界の市場 Radiopharmaceuticals: Technologies and Global Markets
出版日: 2016年12月21日 ページ情報: 英文 189 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の放射性医薬品の市場は2016年から2021年にかけて12.4%のCAGR (年間複合成長率) で推移し、2015年の57億ドルから、2016年には約65億ドル、2021年には116億ドルの規模に成長すると予測されています。

当レポートは、世界の放射性医薬品の各種技術と市場を調査し、市場の定義と概要、法規制環境と関連課題、パイプラインの動向、用途・製品区分・製造法・地域など各種区分別の動向と市場規模の推移と予測、市場成長への各種影響因子の分析、特許データ、市場のリーダーと市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • 放射性医薬品の利用
  • 定義
  • 経緯・背景
  • 放射性核種の源
  • 医療で一般的に用いられる放射性核種
  • 放射性医薬品の調剤
  • 放射性医薬品の用途
  • 放射性医薬品の長所

第4章 法規制面の状況

  • 新薬の承認と申請
  • 密封小線源の承認
  • 安全性アラート
  • 有害事象報告
  • 薬剤の不足

第5章 新たな開発動向

  • パイプライン製品
  • 放射性医薬品における他の重要な新規開発

第6章 市場分析

  • タイプ別市場
    • 市場概要
    • 市場収益
    • 市場シェア
    • 診断用放射性医薬品
      • 診断用テストタイプ別
      • PET用放射性医薬品
      • SPECT用放射性医薬品
      • その他
    • 治療用放射性医薬品
      • タイプ別
      • アルファ放出体
      • ベータ放出体
      • 密封小線源シード
  • 診断用放射性医薬品市場:地域別
    • 市場概要
    • 市場収益
    • 市場シェア
  • 治療用放射性医薬品市場:地域別
    • 市場概要
    • 市場収益
    • 市場シェア
  • 放射性医薬品市場:製造法別
    • 粒子加速装置 (サイクロトロン)
    • 原子炉
    • 放射性核種ジェネレーター
      • 市場概要
      • 市場収益
      • 市場シェア

第7章 産業構造

  • 診断用放射性医薬品
    • PET診断
      • 市場リーダー
      • 市場シェア
    • SPECT診断
      • 市場リーダー
      • 市場シェア
    • その他
      • 市場リーダー
      • 市場シェア
  • 治療用放射性医薬品
    • 市場リーダー
    • 市場シェア

第8章 特許分析

第9章 現況

  • 市場への影響因子
    • 推進因子
    • 障壁
  • 協力・M&A

第10章 企業プロファイル

  • ACTINIUM PHARMACEUTICALS INC.
  • ADVANCED ACCELERATOR APPLICATIONS SA
  • ADVANCED MEDICAL ISOTOPE CORP.
  • ALLIANCE MEDICAL GROUP
  • ALSERES PHARMACEUTICALS INC.
  • AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION
  • AYTU BIOSCIENCE INC.
  • BARD MEDICAL
  • BAYER PHARMA AG
  • BLUE EARTH DIAGNOSTICS LTD.
  • BOARD OF RADIATION AND ISOTOPE TECHNOLOGY
  • BRACCO DIAGNOSTIC INC.
  • BTG INTERNATIONAL LTD.
  • CARDINAL HEALTH INC.
  • ELI LILLY AND COMPANY
  • 富士フイルムRIファーマ
  • GE HEALTHCARE
  • IBA MOLECULAR
  • ISORAY MEDICAL INC.
  • ISO-TEX DIAGNOSTICS INC.
  • JUBILANT DRAXIMAGE INC.
  • LANTHEUS MEDICAL IMAGING INC.
  • MALLINCKRODT PLC
  • NATIONAL CENTRE FOR NUCLEAR RESEARCH POLATOM
  • NATIONAL INSTITUTE FOR RADIOELEMENTS (IRE)
  • NAVIDEA BIOPHARMACEUTICALS INC.
  • NORDION INC.
  • NTP RADIOISOTOPES SOC LTD
  • PHARMALUCENCE INC.
  • PIRAMAL IMAGING SA
  • SIEMENS HEALTHCARE GMBH
  • SPECTRUM PHARMACEUTICALS INC.
  • TRIAD ISOTOPES INC.
  • ZEVACOR MOLECULAR

第11章 略語解説

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM171B

The global market radiopharmaceuticals were valued at nearly $5.1 billion and $5.7 billion in 2014 and 2015, respectively. This market is expected to increase from nearly $6.5 billion in 2016 to $11.6 billion in 2021 at a compound annual growth rate (CAGR) of 12.4% for 2016-2021.

This report provides:

  • An overview of the global market for radiopharmaceuticals and related technologies.
  • Analyses of global market trends, with data from 2014 and 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Information on how radiopharmaceuticals are used to diagnose cancer, tumors, brain diseases, bone diseases, bone marrow diseases, colorectal disease, kidney diseases, liver diseases, lung diseases, and many others.
  • Details concerning the regulatory environment and the impacts of government on the market.
  • Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities
  • Profiles of leading companies in the industry.

image1

REPORT SCOPE

SCOPE OF THE STUDY

This report focuses on the global market for radiopharmaceutical products. Radiopharmaceuticals provide actual mapping of the physiological functions and metabolic activity of organs. They provide highly specific information on organ function and dysfunction. Radiopharmaceuticals can also be used in radiotherapy to destroy dysfunctional cells.

In this report, BCC Research analyzes each global market in terms of applications, regulatory environment, new products and advancements, market projections and market shares. The geographical regions covered in the report are North America and Europe and an emerging markets category. The emerging markets category covers countries that include India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand and Canada.

This report also includes an analysis of relevant patent and comprehensive profiles of leading companies in the radiopharmaceuticals industry. Some of the major global players in the radiopharmaceuticals industry are Advanced Medical Isotope Corp., Advanced Accelerator Applications SA, Bayer AG (Bayer HealthCare Pharmaceuticals Inc.), Bracco S.p.A. (Bracco Imaging S.p.A.), Cardinal Health Inc., Eli Lilly and Co., Fujifilm RI Pharma Co. Ltd. (Fujifilm Corp.), General Electric Co. (GE Healthcare), Jubilant Life Sciences (Jubilant DraxImage Inc.), Lantheus Holdings Inc. (Lantheus Medical Imaging Inc.), Mallinckrodt PLC, Navidea Biopharmaceuticals Inc., Noridon Inc., Piramal Enterprises Ltd. (Piramal Imaging SA), Siemens AG (Siemens PETNET Solutions Inc.) and Triad Isotopes Inc.

ANALYSTS' CREDENTIALS

The study was carried out by a team of professionals in the biotechnology industry. The project manager was Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. She was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and the United States. Her other reports for BCC Research include:

  • Global Markets for Reagents for Chromatography.
  • Global Markets for Spectroscopy Equipment.
  • Global Markets and Technologies for Advanced Drug Delivery Systems.
  • Orthopedic Drugs, Implants and Devices.
  • Global Markets for Medical Imaging Reagents and Analysis Equipment.
  • The Pharmaceutical Regulatory Industry.
  • Global Markets for Media, Sera and Reagents in Biotechnology.
  • Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging.
  • Global Markets for Chiral Technology.
  • Autacoids and Related Drugs: Technologies and Global Markets.
  • Contraceptives: Technologies and Global Markets.
  • Liver Disease Treatments: The Global Market.
  • Hormone Replacement Therapies and Other Hormone Therapies:
  • Global Markets.
  • Cardiovascular Medicine: Diagnostics, Drugs and Devices.
  • Cancer Therapies: Technologies and Global Markets.
  • Medical Imaging Reagents and Analysis Equipment.

The lead consultant for this project was Ms. Shalini Agarwal, who holds a master's degree in business administration and a bachelor's degree in science. She has authored many reports and other publications for various companies while serving as a market research analyst.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYSTS' CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • USES OF RADIOPHARMACEUTICALS
    • DIAGNOSTIC IMAGING
    • IN VIVO FUNCTION
    • IN VITRO STUDIES
    • THERAPEUTIC APPLICATIONS
  • DEFINITIONS
    • NUCLIDE
    • ISOTOPE
    • RADIATION
    • RADIOACTIVITY
    • ALPHA PARTICLES
    • BETA PARTICLES
    • GAMMA RAY
    • RADIOACTIVE DECAY
    • ISOMERIC TRANSITION
    • RADIOISOTOPE
    • RADIOPHARMACEUTICAL PRECURSOR
    • SPECIFIC ACTIVITY
    • LINEAR ENERGY TRANSFER
    • NEGATRON
    • POSITRON
    • TRANSMUTATION
    • HALF-LIFE
    • NUCLEAR MEDICINE
    • RADIOPHARMACY
    • PHARMACOKINETICS
    • MYELOSUPPRESSION
    • CRITICAL ORGAN
  • HISTORY AND BACKGROUND
  • TABLE 1 MILESTONES OF THE DISCOVERY OF RADIOACTIVITY AND NUCLEAR MEDICINE
  • ORIGIN OF RADIONUCLIDES
    • TYPES OF RADIONUCLIDES
      • Primordial Radionuclides
      • Secondary Radionuclides
      • Cosmogenic Radionuclides
    • METHODS OF PRODUCING RADIONUCLIDES
      • Nuclear Fission
      • Charged-particle Bombardment
      • Neutron Activation
      • Radionuclide Generator Systems
    • RADIONUCLIDES BY PRODUCTION TYPE
      • Particle Accelerator-Produced Radionuclides
        • Linear Particle Accelerators
        • Circular Particle Accelerators
        • TABLE 2 COMMON CYCLOTRON-PRODUCED RADIONUCLIDES/RADIOISOTOPES
      • Nuclear Reactor-Produced Radionuclides
      • TABLE 3 COMMON NUCLEAR REACTOR-PRODUCED
    • RADIONUCLIDES/RADIOISOTOPES
    • RADIONUCLIDE GENERATORS
    • TABLE 4 COMMON RADIONUCLIDE PAIRS IN RADIONUCLIDE GENERATORS
  • COMMONLY USED RADIONUCLIDES IN MEDICINE
    • TECHNETIUM-99M
    • IODINE-123
    • IODINE-131
    • FLUORINE-18
    • INDIUM-111
    • THALLIUM-201
    • GALLIUM-67
  • PREPARATION OF RADIOPHARMACEUTICALS
    • RADIOPHARMACEUTICAL PREPARATION KITS
  • APPLICATIONS OF RADIOPHARMACEUTICALS
    • DIAGNOSTIC RADIOPHARMACEUTICALS
    • TABLE 5 COMMON ISOTOPES USED IN DIAGNOSTIC RADIOPHARMACEUTICAL DEVELOPMENT
    • TABLE 6 SELECTED COMMERCIALLY APPROVED DIAGNOSTIC
    • RADIOPHARMACEUTICALS
    • TYPES OF DIAGNOSTIC RADIOPHARMACEUTICALS
      • PET Radiopharmaceuticals
      • SPECT Radiopharmaceuticals
    • THERAPEUTIC RADIOPHARMACEUTICALS
    • TABLE 7 COMMON ISOTOPSES USED IN THERAPEUTIC RADIOPHARMACEUTICAL DEVELOPMENT
      • Radioimmunotherapy
      • TABLE 8 SELECTED COMMERCIALLY APPROVED THERAPEUTIC Alpha Emitters
        • TAT/Alpha-immunotherapy
        • TABLE 9 ADVANTAGES AND DISADVANTAGES OF ALPHA EMITTERS
      • Beta Emitters
      • TABLE 10 ADVANTAGES AND DISADVANTAGES OF BETA EMITTERS
      • Brachytherapy
      • TABLE 11 COMMONLY USED RADIONUCLIDES (RADIATION SOURCES) FOR BRACHYTHERAPY
      • TABLE 12 ADVANTAGES AND DISADVANTAGES OF BRACHYTHERAPY
    • THERANOSTIC AGENTS
  • ADVANTAGES AND DISADVANTAGES OF RADIOPHARMACEUTICALS
  • TABLE 13 ADVANTAGES AND DISADVANTAGES OF RADIOPHARMACEUTICALS

CHAPTER 4 REGULATORY ASPECTS

  • NEW DRUG APPROVALS AND APPLICATIONS
    • INVESTIGATIONAL NEW DRUG
    • NEW DRUG APPLICATION
    • TABLE 14 APPROVALS OF NEW DRUG APPLICATIONS FOR RADIOPHARMACEUTICALS, FROM JANUARY 2014 TO MAY 2016
    • ABBREVIATED NEW DRUG APPLICATION
    • TABLE 15 APPROVALS OF ABBREVIATED NEW DRUG APPLICATIONS FOR RADIOPHARMACEUTICALS, FROM JANUARY 2014 TO MAY 2016
  • APPROVALS FOR RADIONUCLIDE BRACHYTHERAPY SOURCES
    • PREMARKET APPROVAL
    • PREMARKET NOTIFICATION 510(K)
    • TABLE 16 510K APPROVALS FOR RADIONUCLIDE BRACHYTHERAPY SOURCES, JANUARY 2014-MAY 2016
  • SAFETY ALERTS
  • TABLE 17 SAFETY ALERTS ISSUED FOR RADIOPHARMACEUTICALS, FROM JANUARY 2014-MAY 2016
  • ADVERSE EVENT REPORTING
  • TABLE 18 ADVERSE EVENT REPORTING FOR RADIONUCLIDE BRACHYTHERAPY SOURCES, FROM JANUARY 2014-MAY 2016
  • DRUG SHORTAGES
  • TABLE 19 RADIOPHARMACEUTICAL SHORTAGES, THROUGH MAY 2016

CHAPTER 5 NEW DEVELOPMENTS

  • PIPELINE PRODUCTS
  • TABLE 20 CLINICAL TRIALS FOR RADIOPHARMACEUTICALS, THROUGH MAY 2016
  • OTHER SIGNIFICANT NEW DEVELOPMENTS IN RADIOPHARMACEUTICALS
    • GALLIUM-68 PET/CT SCANS

CHAPTER 6 MARKET ANALYSIS

  • MARKET BY RADIOPHARMACEUTICAL TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 21 GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, THROUGH 2021 ($ MILLIONS)
    • FIGURE 1 GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2014-2021 ($ MILLIONS)
    • MARKET SHARES
    • TABLE 22 GLOBAL MARKET SHARES OF RADIOPHARMACEUTICALS, BY TYPE, 2015 (%)
    • FIGURE 2 GLOBAL MARKET SHARES OF RADIOPHARMACEUTICALS, BY TYPE, 2015 (%)
    • DIAGNOSTIC RADIOPHARMACEUTICALS
      • Diagnostic Radiopharmaceuticals Market by Type of Diagnostic Test
        • Market Overview
        • Market Revenue
        • TABLE 23 GLOBAL MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF DIAGNOSTIC TEST, THROUGH 2021 ($ MILLIONS)
        • FIGURE 3 GLOBAL MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF DIAGNOSTIC TEST, 2014-2021 ($ MILLIONS)
        • PET Radiopharmaceuticals
          • PET Radiopharmaceuticals Market by Region
            • Revenue of PET Radiopharmaceuticals Market by
            • Region
            • TABLE 24 GLOBAL MARKET FOR PET RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
            • FIGURE 4 GLOBAL MARKET FOR PET RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
          • PET Radiopharmaceuticals Market by Type of Radionuclide
            • Revenue for PET Radiopharmaceuticals Market by
            • Type of Radionuclide 91
            • TABLE 25 GLOBAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
            • FIGURE 5 GLOBAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
      • SPECT Radiopharmaceuticals
        • SPECT Radiopharmaceuticals Market by Region
          • Revenue of SPECT Radiopharmaceuticals Market by
          • Region 95
          • TABLE 26 GLOBAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
          • FIGURE 6 GLOBAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
        • SPECT Radiopharmaceuticals Market by Type of
          • Radionuclide
          • Revenue of SPECT Radiopharmaceuticals Market by
          • Type of Radionuclide
          • TABLE 27 GLOBAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
          • FIGURE 7 GLOBAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
      • Other Diagnostic Radiopharmaceuticals
        • Other Diagnostic Radiopharmaceuticals Market by Region
          • Revenue of Other Diagnostic Radiopharmaceuticals Market by Region
          • TABLE 28 GLOBAL MARKET FOR OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
          • FIGURE 8 GLOBAL MARKET FOR OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
        • Other Diagnostic Radiopharmaceuticals Market by Type of Radionuclide
        • Revenue of Other Diagnostic Radiopharmaceuticals Market by Type of Radionuclide
        • TABLE 29 GLOBAL MARKET FOR OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
        • FIGURE 9 GLOBAL MARKET FOR OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
      • Market Share of Diagnostics Radiopharmaceutical by Type
      • TABLE 30 MARKET SHARES OF DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF DIAGNOSTIC TEST, 2015 (%)
      • FIGURE 10 MARKET SHARES OF DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF DIAGNOSTIC TEST, 2015 (%)
    • THERAPEUTIC RADIOPHARMACEUTICALS
      • Therapeutic Radiopharmaceuticals by Type
      • Market Overview
      • Market Revenue
      • TABLE 31 GLOBAL MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS, BY TYPE, THROUGH 2021 ($ MILLIONS)
      • FIGURE 11 GLOBAL MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS, BY TYPE, 2014-2021 ($ MILLIONS)
        • Alpha Emitters
          • Alpha Emitters Market by Region
            • Revenue of Alpha Emitters Market by Region
            • TABLE 32 GLOBAL MARKET FOR ALPHA EMITTERS, BY REGION, THROUGH 2021 ($ MILLIONS)
            • FIGURE 12 GLOBAL MARKET FOR ALPHA EMITTERS, BY REGION, 2014-2021 ($ MILLIONS)
          • Alpha Emitters Market by Type of Radionuclide
            • Revenue of Alpha Emitters Market by Type of
            • Radionuclide
            • TABLE 33 GLOBAL MARKET FOR ALPHA EMITTERS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
            • FIGURE 13 GLOBAL MARKET FOR ALPHA EMITTERS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
        • Beta Emitters
          • Beta Emitters Market by Region
            • Revenue of Beta Emitters Market by Region
            • TABLE 34 GLOBAL MARKET FOR BETA EMITTERS, BY REGION, THROUGH 2021 ($ MILLIONS)
            • FIGURE 14 GLOBAL MARKET FOR BETA EMITTERS, BY REGION, 2014-2021 ($ MILLIONS)
          • Beta Emitters Market by Type of Radionuclide
            • Revenue of Beta Emitters Market by Type of
            • Radionuclide
            • TABLE 35 GLOBAL MARKET FOR BETA EMITTERS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
            • FIGURE 15 GLOBAL MARKET FOR BETA EMITTERS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
        • Brachytherapy Seeds
          • LDR Brachytherapy Seeds Market by Region
            • Revenue of LDR Brachytherapy Seeds Market by Region
            • TABLE 36 GLOBAL MARKET FOR LDR BRACHYTHERAPY SEEDS, BY REGION, THROUGH 2021 ($ MILLIONS)
            • FIGURE 16 GLOBAL MARKET FOR LDR BRACHYTHERAPY SEEDS, BY REGION, 2014-2021 ($ MILLIONS)
          • Brachytherapy Seeds Market by Type of Radionuclide
            • Revenue of Brachytherapy Seeds Market by Type of Radionuclide
            • TABLE 37 GLOBAL MARKET FOR BRACHYTHERAPY SEEDS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
            • FIGURE 17 GLOBAL MARKET FOR BRACHYTHERAPY SEEDS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
      • Market Shares of Therapeutic Radiopharmaceuticals by Type
      • TABLE 38 MARKET SHARES OF THERAPEUTIC RADIOPHARMACEUTICALS, BY TYPE, 2015 (%)
      • FIGURE 18 MARKET SHARES OF THERAPEUTIC RADIOPHARMACEUTICALS, BY TYPE, 2015 (%)
  • DIAGNOSTIC RADIOPHARMACEUTICALS MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 39 GLOBAL MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 19 GLOBAL MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
    • MARKET SHARES
    • TABLE 40 MARKET SHARES OF DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2015 (%)
    • FIGURE 20 MARKET SHARES OF DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2015 (%)
  • THERAPEUTIC RADIOPHARMACEUTICALS MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 41 GLOBAL MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 21 GLOBAL MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
    • MARKET SHARES
    • TABLE 42 MARKET SHARES OF THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, 2015 (%)
    • FIGURE 22 MARKET SHARES OF THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, 2015 (%)
  • RADIOPHARMACEUTICALS MARKET BY PRODUCTION METHOD
    • PARTICLE ACCELERATORS (CYCLOTRONS)
    • NUCLEAR REACTORS
    • RADIONUCLIDE GENERATORS
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 43 GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY PRODUCTION METHOD, THROUGH 2021 ($ MILLIONS)
    • FIGURE 23 GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY PRODUCTION METHOD, 2014-2021 ($ MILLIONS)
    • MARKET SHARES
    • TABLE 44 MARKET SHARES OF RADIOPHARMACEUTICALS, BY PRODUCTION METHOD, 2015 (%)
    • FIGURE 24 MARKET SHARES OF RADIOPHARMACEUTICALS, BY PRODUCTION METHOD, 2015 (%)

CHAPTER 7 INDUSTRY STRUCTURE

  • DIAGNOSTIC RADIOPHARMACEUTICALS
    • PET RADIOPHARMACEUTICALS
      • Market Leaders
      • TABLE 45 LEADING MANUFACTURERS/SUPPLIERS OF PET RADIOPHARMACEUTICALS, 2015
      • Market Shares
      • TABLE 46 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PET RADIOPHARMACEUTICALS, 2015 (%)
      • FIGURE 25 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PET RADIOPHARMACEUTICALS, 2015 (%)
    • SPECT RADIOPHARMACEUTICALS
      • Market Leaders
      • TABLE 47 LEADING MANUFACTURERS/SUPPLIERS OF SPECT RADIOPHARMACEUTICALS, 2015
      • Market Shares
      • TABLE 48 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SPECT RADIOPHARMACEUTICALS, 2015 (%)
      • FIGURE 26 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SPECT RADIOPHARMACEUTICALS, 2015 (%)
    • OTHER DIAGNOSTIC RADIOPHARMACEUTICALS
      • Market Leaders
      • TABLE 49 LEADING MANUFACTURERS/SUPPLIERS OF OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, 2015
      • Market Shares
      • TABLE 50 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, 2015 (%)
      • FIGURE 27 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, 2015 (%)
  • THERAPEUTIC RADIOPHARMACEUTICALS
    • MARKET LEADERS
    • TABLE 51 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC RADIOPHARMACEUTICALS, 2015
    • MARKET SHARES
    • TABLE 52 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC RADIOPHARMACEUTICALS, 2015 (%)
    • FIGURE 28 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC RADIOPHARMACEUTICALS, 2015 (%)

CHAPTER 8 PATENT ANALYSIS

  • PATENTS BY YEAR
  • TABLE 53 NUMBER OF SIGNIFICANT PATENTS FOR RADIOPHARMACEUTICALS/ RADIONUCLIDES, JANUARY 2014-MAY 2016
  • FIGURE 29 NUMBER OF SIGNIFICANT PATENTS FOR RADIOPHARMACAUTICALS/ RADIONUCLIDES, FROM JANUARY 2014-MAY 2016
  • PATENTS BY TYPE OF RADIONUCLIDE
  • TABLE 54 PATENTS BY TYPE OF RADIONUCLIDE, JANUARY 2014-MAY 2016
  • FIGURE 30 PATENTS BY TYPE OF RADIONUCLIDE, JANUARY 2014-MAY 2016
  • PATENTS BY COMPANY
  • TABLE 55 NUMBER OF PATENTS BY COMPANY, JANUARY 2014-MAY 2016
  • PATENTS BY COUNTRY
  • TABLE 56 NUMBER OF PATENTS BY COUNTRY, JANUARY 2014-MAY 2016
  • FIGURE 31 NUMBER OF PATENTS BY COUNTRY, JANUARY 2014-MAY 2016
  • TABLE 57 PATENT SHARES BY COUNTRY, JANUARY 2014-MAY 2016 (%)
  • FIGURE 32 PATENT SHARES BY COUNTRY, JANUARY 2014-MAY 2016 (%)
  • PATENTS BY ASSIGNEE TYPE
  • TABLE 58 NUMBER OF PATENTS BY ASSIGNEE TYPE, JANUARY 2014 -MAY 2016
  • FIGURE 33 NUMBER OF PATENTS BY ASSIGNEE TYPE, JANUARY 2014-MAY 2016

CHAPTER 9 CURRENT SITUATION

  • FACTORS AFFECTING THE RADIOPHARMACEUTICALS MARKET
    • DRIVERS OF THE RADIOPHARMACEUTICALS MARKET
      • Aging Population
        • Increasing Incidence of Life-threatening Diseases
      • Growing Focus on Early Diagnosis and Treatment
      • Launch of New Radiopharmaceuticals and Widening Applications
      • Growing Healthcare Spending in Emerging Regions
      • Increasing Number of Cyclotrons
      • Increasing Amount of Nuclear Imaging Equipment
      • Technological Advancements
    • RESTRAINTS AND CHALLENGES OF THE MARKET
      • Limited Global Supply of Medical Isotopes
      • Reimbursement Policies
      • Healthcare Reforms and Budgetary Constraints in Developed Countries
      • Regulatory Issues
  • COLLABORATIONS, MERGERS AND ACQUISITIONS

CHAPTER 10 COMPANY PROFILES

  • ACTINIUM PHARMACEUTICALS INC.
  • ADVANCED ACCELERATOR APPLICATIONS SA
  • ADVANCED MEDICAL ISOTOPE CORP.
  • ALLIANCE MEDICAL GROUP
  • ALSERES PHARMACEUTICALS INC.
  • AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION
  • AYTU BIOSCIENCE INC.
  • BARD MEDICAL
  • BAYER PHARMA AG
  • BLUE EARTH DIAGNOSTICS LTD.
  • BOARD OF RADIATION AND ISOTOPE TECHNOLOGY
  • BRACCO DIAGNOSTIC INC.
  • BTG INTERNATIONAL LTD.
  • CARDINAL HEALTH INC.
  • ELI LILLY AND COMPANY
  • FUJIFILM RI PHARMA CO. LTD.
  • GE HEALTHCARE
  • IBA MOLECULAR
  • ISORAY MEDICAL INC.
  • ISO-TEX DIAGNOSTICS INC.
  • JUBILANT DRAXIMAGE INC.
  • LANTHEUS MEDICAL IMAGING INC.
  • MALLINCKRODT PLC
  • NATIONAL CENTRE FOR NUCLEAR RESEARCH POLATOM
  • NATIONAL INSTITUTE FOR RADIOELEMENTS (IRE)
  • NAVIDEA BIOPHARMACEUTICALS INC.
  • NORDION INC.
  • NTP RADIOISOTOPES SOC LTD
  • PHARMALUCENCE INC.
  • PIRAMAL IMAGING SA
  • SIEMENS HEALTHCARE GMBH
  • SPECTRUM PHARMACEUTICALS INC.
  • TRIAD ISOTOPES INC.
  • ZEVACOR MOLECULAR

CHAPTER 11 ABBREVIATIONS

  • TABLE 59 ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 1 MILESTONES OF THE DISCOVERY OF RADIOACTIVITY AND NUCLEAR MEDICINE
  • TABLE 2 COMMON CYCLOTRON-PRODUCED RADIONUCLIDES/RADIOISOTOPES
  • TABLE 3 COMMON NUCLEAR REACTOR-PRODUCED
  • RADIONUCLIDES/RADIOISOTOPES
  • TABLE 4 COMMON RADIONUCLIDE PAIRS IN RADIONUCLIDE GENERATORS
  • TABLE 5 COMMON ISOTOPES USED IN DIAGNOSTIC RADIOPHARMACEUTICAL DEVELOPMENT
  • TABLE 6 SELECTED COMMERCIALLY APPROVED DIAGNOSTIC RADIOPHARMACEUTICALS
  • TABLE 7 COMMON ISOTOPSES USED IN THERAPEUTIC RADIOPHARMACEUTICAL DEVELOPMENT
  • TABLE 8 SELECTED COMMERCIALLY APPROVED THERAPEUTIC RADIOPHARMACEUTICALS
  • TABLE 9 ADVANTAGES AND DISADVANTAGES OF ALPHA EMITTERS
  • TABLE 10 ADVANTAGES AND DISADVANTAGES OF BETA EMITTERS
  • TABLE 11 COMMONLY USED RADIONUCLIDES (RADIATION SOURCES) FOR BRACHYTHERAPY
  • TABLE 12 ADVANTAGES AND DISADVANTAGES OF BRACHYTHERAPY
  • TABLE 13 ADVANTAGES AND DISADVANTAGES OF RADIOPHARMACEUTICALS
  • TABLE 14 APPROVALS OF NEW DRUG APPLICATIONS FOR RADIOPHARMACEUTICALS, FROM JANUARY 2014 TO MAY 2016
  • TABLE 15 APPROVALS OF ABBREVIATED NEW DRUG APPLICATIONS FOR RADIOPHARMACEUTICALS, FROM JANUARY 2014 TO MAY 2016
  • TABLE 16 510K APPROVALS FOR RADIONUCLIDE BRACHYTHERAPY SOURCES, JANUARY 2014-MAY 2016
  • TABLE 17 SAFETY ALERTS ISSUED FOR RADIOPHARMACEUTICALS, FROM JANUARY 2014-MAY 2016
  • TABLE 18 ADVERSE EVENT REPORTING FOR RADIONUCLIDE BRACHYTHERAPY SOURCES, FROM JANUARY 2014-MAY 2016
  • TABLE 19 RADIOPHARMACEUTICAL SHORTAGES, THROUGH MAY 2016
  • TABLE 20 CLINICAL TRIALS FOR RADIOPHARMACEUTICALS, THROUGH MAY 2016
  • TABLE 21 GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 22 GLOBAL MARKET SHARES OF RADIOPHARMACEUTICALS, BY TYPE, 2015 (%)
  • TABLE 23 GLOBAL MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF DIAGNOSTIC TEST, THROUGH 2021 ($ MILLIONS)
  • TABLE 24 GLOBAL MARKET FOR PET RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 25 GLOBAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
  • TABLE 26 GLOBAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 27 GLOBAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
  • TABLE 28 GLOBAL MARKET FOR OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 29 GLOBAL MARKET FOR OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
  • TABLE 30 MARKET SHARES OF DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF DIAGNOSTIC TEST, 2015 (%)
  • TABLE 31 GLOBAL MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS, BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 32 GLOBAL MARKET FOR ALPHA EMITTERS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 33 GLOBAL MARKET FOR ALPHA EMITTERS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
  • TABLE 34 GLOBAL MARKET FOR BETA EMITTERS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 35 GLOBAL MARKET FOR BETA EMITTERS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
  • TABLE 36 GLOBAL MARKET FOR LDR BRACHYTHERAPY SEEDS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 37 GLOBAL MARKET FOR BRACHYTHERAPY SEEDS, BY TYPE OF RADIONUCLIDE, THROUGH 2021 ($ MILLIONS)
  • TABLE 38 MARKET SHARES OF THERAPEUTIC RADIOPHARMACEUTICALS, BY TYPE, 2015 (%)
  • TABLE 39 GLOBAL MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 40 MARKET SHARES OF DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2015 (%)
  • TABLE 41 GLOBAL MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 42 MARKET SHARES OF THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, 2015 (%)
  • TABLE 43 GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY PRODUCTION METHOD, THROUGH 2021 ($ MILLIONS)
  • TABLE 44 MARKET SHARES OF RADIOPHARMACEUTICALS, BY PRODUCTION METHOD, 2015 (%)
  • TABLE 45 LEADING MANUFACTURERS/SUPPLIERS OF PET RADIOPHARMACEUTICALS, 2015
  • TABLE 46 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PET RADIOPHARMACEUTICALS, 2015 (%)
  • TABLE 47 LEADING MANUFACTURERS/SUPPLIERS OF SPECT RADIOPHARMACEUTICALS, 2015
  • TABLE 48 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SPECT RADIOPHARMACEUTICALS, 2015 (%)
  • TABLE 49 LEADING MANUFACTURERS/SUPPLIERS OF OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, 2015
  • TABLE 50 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, 2015 (%)
  • TABLE 51 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC RADIOPHARMACEUTICALS, 2015
  • TABLE 52 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC RADIOPHARMACEUTICALS, 2015 (%)
  • TABLE 53 NUMBER OF SIGNIFICANT PATENTS FOR RADIOPHARMACEUTICALS/ RADIONUCLIDES, JANUARY 2014-MAY 2016
  • TABLE 54 PATENTS BY TYPE OF RADIONUCLIDE, JANUARY 2014-MAY 2016
  • TABLE 55 NUMBER OF PATENTS BY COMPANY, JANUARY 2014-MAY 2016
  • TABLE 56 NUMBER OF PATENTS BY COUNTRY, JANUARY 2014-MAY 2016
  • TABLE 57 PATENT SHARES BY COUNTRY, JANUARY 2014-MAY 2016 (%)
  • TABLE 58 NUMBER OF PATENTS BY ASSIGNEE TYPE, JANUARY 2014 -MAY 2016
  • TABLE 59 ABBREVIATIONS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 1 GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2014-2021 ($ MILLIONS)
  • FIGURE 2 GLOBAL MARKET SHARES OF RADIOPHARMACEUTICALS, BY TYPE, 2015 (%)
  • FIGURE 3 GLOBAL MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF DIAGNOSTIC TEST, 2014-2021 ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR PET RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 5 GLOBAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
  • FIGURE 6 GLOBAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 7 GLOBAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
  • FIGURE 8 GLOBAL MARKET FOR OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 9 GLOBAL MARKET FOR OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
  • FIGURE 10 MARKET SHARES OF DIAGNOSTIC RADIOPHARMACEUTICALS, BY TYPE OF DIAGNOSTIC TEST, 2015 (%)
  • FIGURE 11 GLOBAL MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS, BY TYPE, 2014-2021 ($ MILLIONS)
  • FIGURE 12 GLOBAL MARKET FOR ALPHA EMITTERS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 13 GLOBAL MARKET FOR ALPHA EMITTERS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
  • FIGURE 14 GLOBAL MARKET FOR BETA EMITTERS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 15 GLOBAL MARKET FOR BETA EMITTERS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
  • FIGURE 16 GLOBAL MARKET FOR LDR BRACHYTHERAPY SEEDS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 17 GLOBAL MARKET FOR BRACHYTHERAPY SEEDS, BY TYPE OF RADIONUCLIDE, 2014-2021 ($ MILLIONS)
  • FIGURE 18 MARKET SHARES OF THERAPEUTIC RADIOPHARMACEUTICALS, BY TYPE, 2015 (%)
  • FIGURE 19 GLOBAL MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 20 MARKET SHARES OF DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2015 (%)
  • FIGURE 21 GLOBAL MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 22 MARKET SHARES OF THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, 2015 (%)
  • FIGURE 23 GLOBAL MARKET FOR RADIOPHARMACEUTICALS, BY PRODUCTION METHOD, 2014-2021 ($ MILLIONS)
  • FIGURE 24 MARKET SHARES OF RADIOPHARMACEUTICALS, BY PRODUCTION METHOD, 2015 (%)
  • FIGURE 25 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PET RADIOPHARMACEUTICALS, 2015 (%)
  • FIGURE 26 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SPECT RADIOPHARMACEUTICALS, 2015 (%)
  • FIGURE 27 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OTHER DIAGNOSTIC RADIOPHARMACEUTICALS, 2015 (%)
  • FIGURE 28 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC RADIOPHARMACEUTICALS, 2015 (%)
  • FIGURE 29 NUMBER OF SIGNIFICANT PATENTS FOR RADIOPHARMACAUTICALS/RADIONUCLIDES, FROM JANUARY 2014-MAY 2016
  • FIGURE 30 PATENTS BY TYPE OF RADIONUCLIDE, JANUARY 2014-MAY 2016
  • FIGURE 31 NUMBER OF PATENTS BY COUNTRY, JANUARY 2014-MAY 2016
  • FIGURE 32 PATENT SHARES BY COUNTRY, JANUARY 2014-MAY 2016 (%)
  • FIGURE 33 NUMBER OF PATENTS BY ASSIGNEE TYPE, JANUARY 2014-MAY 2016
Back to Top